PositoAI/ US/ REGENXBIO Inc.

REGENXBIO Inc.

NasdaqGS: RGNX · Healthcare

Positivity Index

#5,798 / 6,774

Global

#3,221 / 4,000

United States

Positivity Score

15,258

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

REGENXBIO Inc. — Overview & Financial Snapshot

REGENXBIO Inc. (NasdaqGS: RGNX) is a Healthcare company, ranked #5,798 of 6,774 companies globally and #3,221 of 4,000 in United States on PositoAI, with a Positivity Score of 15,258. Its market capitalisation is ₹4,467.66 Cr ($473.31M), P/E ratio is -1.9 and P/B ratio is 6.60. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

P/B Ratio 6.60

P/E Ratio -1.9

D/E Ratio 3.49

ROE -137.63%

Owes vs Owns ? 0.81× High $0.81 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-356.80$-3.78

Forward EPS ₹-280.81$-2.98

Beta 1.13

Market Cap ₹4,467.66 Cr$473.31M

What these numbers mean →

What does REGENXBIO Inc. do?

What is REGENXBIO Inc.'s P/E and P/B ratio?

REGENXBIO Inc. has a P/E ratio of -1.9 and a P/B ratio of 6.60.

What is REGENXBIO Inc.'s debt-to-equity ratio?

REGENXBIO Inc. has a debt-to-equity ratio of 3.49.

How much does REGENXBIO Inc. owe compared with what it owns?

REGENXBIO Inc. owes $0.81 for every $1 it owns (balance sheet Jun 2026), which is high.

What is REGENXBIO Inc.'s Positivity rank?

REGENXBIO Inc. is ranked #5,798 of 6,774 companies globally and #3,221 of 4,000 in United States on PositoAI, with a Positivity Score of 15,258.

Does REGENXBIO Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for REGENXBIO Inc..

Where can I read the latest news about REGENXBIO Inc.?

Recent headlines about REGENXBIO Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does REGENXBIO Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of REGENXBIO Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.